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long-term follow-up study. Using the data from the follow-
up period, background and efficacy in patients from Taiwan 
and Japan, as well as the rates of tumor shrinkage in locally 
advanced and metastatic patients (Waterfall plot) were also 
analyzed.
Methods The results of the primary analysis were recon-
firmed, and subset analysis of overall survival and progres-
sion-free survival was performed based on the overall sur-
vival data updated by the cut-off date of 31st July in 2011.
Results The median follow-up period was 29.8 months, 
and 795 deaths occurred (95.6%). The median overall sur-
vival was 8.8 months for gemcitabine, 9.7 months for S-1 
(hazard ratio [HR], 0.96; 97.5% confidence interval [CI], 
0.79–1.17), and 9.9 months for GS (HR 0.91; 97.5% CI 
Abstract 
Purpose The GEST study showed non-inferiority of S-1 
but not superiority of gemcitabine plus S-1 (GS) to gem-
citabine alone for overall survival with the data by the cut-
off date of 31st July in 2010 for chemo-naïve patients with 
advanced pancreatic cancer. We considered it important 
to determine whether S-1 maintains non-inferiority after 
a long-term follow-up in the GEST study and to obtain a 
firm positive conclusion. In addition, it may be an interest-
ing challenge to explore the efficacious profile of GS in the 
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0.75–1.11). In patients with performance status (PS) 0, the 
median overall survival was 9.8 months for gemcitabine, 
10.9 months for S-1, and 10.5 months for GS. In patients 
with PS 1, the median overall survival was 6.2 months for 
gemcitabine, 6.3 months for S-1, and 9.6 months for GS.
Conclusion Our survey reconfirmed the non-inferiority 
of S-1 to gemcitabine and showed S-1 can be used as one 
of the standard treatment options for advanced pancreatic 
cancer.
Trial registration ClinicalTrials.gov: NCT00498225.
Keywords Pancreatic cancer · Gemcitabine · S-1 · 
Updated data · Subgroup analysis
Introduction
In various clinical trials, gemcitabine has been adapted as a 
standard treatment in patients with advanced unresectable 
pancreatic cancer (Burris et al. 1997). Recently, it has been 
shown that gemcitabine plus erlotinib (Moore et al. 2007), 
a combination of 5-fluorouracil, leucovorin, irinotecan, 
and oxaliplatin (FOLFIRINOX) (Conroy et  al. 2011), and 
gemcitabine plus albumin-bound paclitaxel (nab-paclitaxel) 
(Von Hoff et  al. 2013) are superior to gemcitabine alone. 
Concerns have been raised about the risk of adverse events 
of these combination chemotherapy regimens, because 
medical condition is not so good in patients with advanced 
pancreatic cancer. There are still unmet needs in the first-
line chemotherapy especially for its feasibility.
An oral fluoropyrimidine, S-1 (TS-1; a combination of 
tegafur, gimeracil, and oteracil; Taiho Pharmaceutical Co. 
Ltd., Tokyo, Japan, http://www.taiho.co.jp/) is also used for 
treatment of pancreatic cancer in Japan. Starting in 2007, 
we performed a randomized three-arm phase III study to 
evaluate the non-inferiority of S-1 monotherapy and supe-
riority of gemcitabine plus S-1 (GS) to gemcitabine in 
patients with locally advanced and metastatic pancreatic 
cancer (GEST study). The results demonstrated that S-1 
monotherapy was non-inferior to gemcitabine in terms of 
overall survival (OS) (Ueno et al. 2013). While OS in the 
GS group was not significantly better than that in the gem-
citabine, a survival benefit was suggested in the subgroups 
of patients with locally advanced disease and those with 
performance status (PS) 1.
Recently, FOLFIRINOX and gemcitabine plus nab-
paclitaxel, compared with gemcitabine alone, showed sig-
nificantly prolonged survival; however, both regimens had 
increased toxicity. Monotherapy with gemcitabine or S-1, 
associated with mild adverse events, is still recognized as 
a standard treatment option in the guideline from Japan 
Pancreas Society. We considered it important to determine 
whether S-1 maintains non-inferiority after a long-term 
follow-up in the GEST study and to obtain a firm positive 
conclusion. In addition, it may be an interesting challenge 
to explore the efficacious profile of GS in the long-term 
follow-up study.
In the previous analysis, OS was estimated on the basis 
of 710 deaths (85.3%) among the 832 patients (median 
follow-up, 18.4 months). In the present study, we followed-
up the survivors and updated the OS data to obtain more 
robust conclusions. We now report the long-term outcomes 
of the GEST study and the detail results of the additional 
analysis.
Patients and methods
The details of the patient characteristics and study methods 
were reported previously (Ueno et al. 2013).
Patients
The main eligibility criteria were as follows: locally 
advanced or metastatic pancreatic cancer; histologically or 
cytologically confirmed diagnosis of adenocarcinoma; no 
prior chemotherapy or radiotherapy for pancreatic cancer; 
age of 20–80 years; Eastern Cooperative Oncology Group 
PS of 0–1; and adequate main organ function. Written 
informed consent was obtained from all eligible patients.
Study design and treatment
This phase III study was a multicenter, open-label, rand-
omized controlled trial, sponsored by Taiho Pharmaceuti-
cal Co. Ltd. in Japan and TTY Biopharm Co. Ltd. in Tai-
wan. The study was performed as a post-marketing study 
in Japan and a registration study in Taiwan, and was in 
compliance with the Declaration of Helsinki. The study 
was registered with ClinicalTrials.gov (NCT00498225) and 
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approved by the institutional review board or ethics com-
mittee of each participating center.
The patients were randomly assigned to one of three 
treatment groups in a 1:1:1 ratio with minimization method 
stratifying by extent of disease (locally advanced vs. meta-
static) and institution. The patients assigned to gemcit-
abine alone were given gemcitabine (1000  mg/m2) as an 
intravenous infusion over the course of 30 min on days 1, 
8, and 15 in a 28-day cycle. The patients assigned to S-1 
alone were given S-1 orally twice-daily at a dose based on 
their body-surface area (<1.25  m2, 80  mg/day; ≥1.25 to 
<1.5 m2, 100 mg/day; ≥1.5 m2, 120 mg/day) on days 1–28 
in a 42-day cycle. The patients assigned to GS received 
gemcitabine (1000  mg/m2) as an intravenous infusion on 
days 1 and 8 plus S-1 orally twice-daily at a dose based on 
their body-surface area (<1.25  m2, 60  mg/day; ≥1.25 to 
<1.5 m2, 80 mg/day; ≥1.5 m2, 100 mg/day) on days 1–14 
in a 21-day cycle.
Assessments
OS was calculated on the basis of follow-up data available 
at the cut-off point of 31 June 2011. Because other data 
were not updated by follow-up, progression-free survival 
(PFS) was calculated on the basis of the previous main 
analysis at the cut-off point of 31 July 2010 (Ueno et  al. 
2013). Objective tumor response was assessed accord-
ing to the Response Evaluation Criteria in Solid Tumors 
(RECIST), version 1.1. We further performed exploratory 
subgroup analyses of OS and PFS not pre-specified in the 
protocol according to PS and disease extension, and sepa-
rately assessed long-term survival in Japanese and Taiwan-
ese patients.
Statistical analysis
Data for patients included in the full analysis set (FAS) 
were analyzed. The FAS population was composed of all 
randomized subjects with written informed consent. The 
Kaplan–Meier method was used to estimate the distribution 
of events over time in each treatment group. The 95% con-
fidence intervals (CIs) for median survival time were calcu-
lated using the method of Brookmeyer and Crowley (1982). 
The 95% CIs for cumulative survival rates were calculated 
using Greenwood’s formula (Kalbfleisch et al. 1980). Haz-
ard ratios (HRs) were estimated by a Cox-proportional 
hazards model, stratified by country (Japan vs. Taiwan) 
and extent of disease (locally advanced vs. metastatic). For 
HRs, 97.5% CIs were calculated, taking multiplicity into 
account.
In the subgroup analysis, interaction test was performed 
to evaluate heterogeneity in treatment effects among the 
subgroups. All P values were two-sided. Changes in tumor 
size were calculated as the percentage changes from base-
line to nadir. Data analyses were performed with SAS, ver-
sion 9.1.3 (SAS Institute, Cary, NC, USA).
Results
Patients
Between July 2007 and October 2009, a total of 834 
patients were enrolled from 75 institutions in Japan and Tai-
wan (768 in Japan and 66 in Taiwan). In the GS group, two 
patients without written informed consent were excluded 
from the study. The FAS thus comprised 832 patients (Sup-
plemental Fig. 1). The patients’ background characteristics 
were well balanced among the three treatment groups. In 
the previous report (Ueno et al. 2013), the analysis of OS 
was based on 710 deaths, and the remaining 122 patients 
were followed-up for this updated analysis. At the comple-
tion of follow-up, 795 events were observed (95.6%). As 
additional information, the characteristics are separately 
presented for patients in Japan and Taiwan (Table 1). The 
major differences in the patient background characteristics 
between Japan and Taiwan were age (<65/≥65), PS (0/1), 
extent of disease (locally advanced/metastatic), and tumor 
location (head/body/tail).
Efficacy
The median follow-up period was 29.8 months (range 
0.3–46.3). The median OS (mOS) was 8.8 months (95% 
CI 8.0–9.7) in the gemcitabine group, 9.7 months (95% CI 
7.6–10.8) in the S-1 group (HR 0.96; 97.5% CI 0.79–1.17), 
and 9.9 months (95% CI 9.0–11.2) in the GS group (HR 
0.91; 97.5% CI 0.75–1.11) (Fig. 1). The survival rates at 1, 
2, and 3 years were 35.0, 9.4, and 3.4% in the gemcitabine 
group, 38.4, 10.9, and 3.6% in the S-1 group, and 40.4, 
11.6, and 4.1% in the GS group (Supplemental Table 1).
The median tumor shrinkage ratio, calculated using the 
sum of the longest diameter of target lesions at baseline and 
its nadir, was 7.0, 7.9, and 20.9% for pancreatic primary 
lesions, and 3.6, 10.4, and 18.8% for metastatic lesions in 
the gemcitabine group, S-1 group, and GS group, respec-
tively (Supplemental Table 2 and Supplemental Fig. 2a–d).
Subgroup analyses
Results of a subgroup analysis at the primary analysis 
have already been reported (Ueno et al. 2013), and similar 
results were confirmed in this long-term follow-up study. 
Comparing S-1 and gemcitabine, there were no significant 
interactions in any of the subgroups (Fig. 2a). In addition, 
there was no significant interactions that were observed in 
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any subgroups comparing between GS and gemcitabine. 
However, as reported in the primary analysis, there was a 
trend toward the GS group demonstrating better OS than 
the gemcitabine group in patients with a PS of 1 and those 
with locally advanced disease (Fig. 2b). While the hazard 
ratios of the GS group vs. the gemcitabine group were 0.69 
(95% CI 0.51–0.92) in patients with a PS of 1 and 0.67 
(95% CI 0.46–0.99) in patients with locally advanced can-
cer in the report of the primary analysis, and the ratios were 
0.74 (95% CI 0.56–0.98) in patients with a PS of 1 and 0.73 
(95% CI 0.51–1.04) in patients with locally advanced can-
cer in the follow-up analysis.
The survival curves according to PS are shown in 
Fig.  3 In patients with PS 0, the mOS was 9.8 months 
(95% CI 8.8–11.4) in the gemcitabine group, 10.9 months 
(95% CI 10.0–12.2) in the S-1 group (HR 0.96; 97.5% CI 
0.75–1.23), and 10.5 months (95% CI 8.9–12.1) in the GS 
group (HR 1.01; 97.5% CI 0.79–1.30) (Fig. 3a). In patients 
with PS 1, the mOS was 6.2 months (95% CI 4.9–8.3) in 
the gemcitabine group, 6.3 months (95% CI 4.8–7.3) in the 
S-1 group (HR 0.87; 97.5% CI 0.62–1.22), and 9.6 months 
(95% CI 8.0–10.9) in the GS group (HR 0.62; 97.5% CI 
0.44–0.86) (Fig. 3b).
In patients with PS 0, the median PFS (mPFS) was 
4.4 months (95% CI 3.5–5.4) in the gemcitabine group, 
4.2 months (95% CI 3.4–4.7) in the S-1 group (HR 1.03; 
97.5% CI 0.80–1.31), and 6.1 months (95% CI 5.5–7.2) in 
the GS group (HR 0.70; 97.5% CI 0.55–0.90). In patients 
with PS 1, the mPFS was 2.5 months (95% CI 1.8–4.1) in 
the gemcitabine group, 2.3 months (95% CI 1.6–3.8) in the 
S-1 group (HR 1.15; 97.5% CI 0.83–1.61), and 5.4 months 
(95% CI 4.2–6.8) in the GS group (HR 0.52; 97.5% CI 
0.37–0.73).
The proportions of patients who received both drugs 
(gemcitabine and S-1) in their first-line and second-line 
treatments were 63.5% (115/181) in the gemcitabine group 
and 65.7% (117/178) in the S-1 group among patients with 
PS 0, and 44.8% (43/96) in the gemcitabine group and 
55.9% (57/102) in the S-1 group among patients with PS 1.
In Japan, the updated mOS was 8.9 months (95% CI 
8.3–9.7) in the gemcitabine group, 9.7 months (95% CI 
7.7–10.9) in the S-1 group (HR 0.96; 97.5% CI 0.78–1.17), 
and 9.7 months (95% CI 8.9–10.9) in the GS group (HR 
0.91; 97.5% CI 0.74–1.11). In Taiwan, the mOS was 5.3 
months (95% CI 4.2–10.8) in the gemcitabine group, 6.4 
months (95% CI 4.8–11.4) in the S-1 group (HR 1.07; 
97.5% CI 0.50–2.27), and 11.2 months (95% CI 8.0–17.1) 
in the GS group (HR 0.96; 97.5% CI 0.45–2.05). The 
updated cumulative survival rates at 1, 2, and 3 years are 
shown according to country (Japan vs. Taiwan) and disease 
Table 1  Baseline characteristics by country
ECOG PS Eastern Cooperative Oncology Group Performance Status






No. % No. %
Sex
 Male 458 59.8 40 60.6 0.9
 Female 308 40.2 26 39.4
Age (years)
 <65 368 48.0 48 72.7 <0.001
 ≥65 398 52.0 18 27.3
ECOG PS
 0 503 65.7 28 42.4 <0.001
 1 263 34.3 38 57.6
Extent of disease
 Locally advanced 193 25.2 9 13.6 0.04
 Metastatic 573 74.8 57 86.4
Type of tumor
 Adenocarcinoma 754 98.4 66 100 0.31
 Adenosquamous carcinoma 12 1.6 0 0
Pancreas excision
 No 708 92.4 58 87.9 0.19
 Yes 58 7.6 8 12.1
Tumor  locationa
 Head 326 45.6 22 33.3 0.14
 Body 291 38.0 23 34.8 0.61
 Tail 162 21.1 27 40.9 <0.001
Biliary drainage
 No 573 74.8 55 83.3 0.12
 Yes 193 25.2 11 16.7
Fig. 1  Kaplan–Meier curves for updated OS in the full analysis set. 
CI confidence interval, GEM gemcitabine, GS gemcitabine plus S-1, 
HR hazard ratio, OS overall survival
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stage (locally advanced vs. metastatic) in Supplemental 
Table 1.
Discussion
Our analysis of updated follow-up data for the GEST study 
reconfirmed that S-1 was non-inferior to gemcitabine, 
while GS was not shown to be superior to gemcitabine 
(Fig. 1). These findings were consistent with the results of 
the primary analysis. In comparisons of patients in Japan 
and Taiwan, the outcomes for the S-1 group and gemcit-
abine group were found to be slightly poorer in patients in 
Taiwan than in Japan. These differences were attributed to 
the fact that the proportions of patients with PS 1 and meta-
static disease, which are generally associated with poorer 
outcomes, were slightly higher for patients in Taiwan than 
in Japan (Table 1).
At the time of the primary analysis, the subgroup 
analyses showed that OS was better in the GS group 
Fig. 2  Forest plots of treatment effects on OS in subgroup analyses. a S-1 vs. gemcitabine. b GS vs. gemcitabine. CI confidence interval, GEM 
gemcitabine, GS gemcitabine plus S-1, HR hazard ratio, OS overall survival, PS performance status
Fig. 3  Kaplan–Meier plots for updated OS in the subset analysis (a, PS 0; b, PS 1). CI confidence interval, GEM gemcitabine, GS gemcitabine 
plus S-1, HR hazard ratio, PS performance status
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than in the gemcitabine group among patients with PS 1 
as well as in those with locally advanced disease (Ueno 
et al. 2013). In addition, a similar trend was seen with the 
results of analyses in this long-term follow-up. The haz-
ard ratios of OS in patients with a PS of 1 was 0.74 (95% 
CI 0.56–0.98) and in those with locally advanced disease 
was 0.73 (95% CI 0.51–1.04). OS did not differ among 
the three treatment groups in patients with PS 0.
In the GS group, the mOS was similar in patients with 
PS 0 and those with PS 1 (PS 0, 10.5 months; PS 1, 9.6 
months). In contrast, PS 1 was associated with a trend 
toward a shorter mOS in both the gemcitabine group (PS 
0, 9.8 months; PS 1, 6.2 months) and S-1 group (PS 0, 
10.9 months; PS 1, 6.3 months). In the gemcitabine group 
and S-1 group, the proportions of patients who received 
both drugs (gemcitabine and S-1) in the first-line and sec-
ond-line therapies were lower in patients with PS 1 than 
in those with PS 0. In addition, the HR for PFS of PS 1 
in the GS group compared with that in the gemcitabine 
group was very small (HR 0.52; 97.5% CI 0.37–0.73).
These findings suggest that the longer PFS obtained by 
GS may have had a substantial impact on OS, especially 
in the subset of patients with PS 1, because the patients 
with PS 1 in the gemcitabine group and S-1 group could 
not adequately receive effective available drugs as a sec-
ond-line treatment for pancreatic cancer. Consequently, 
survival was unable to be adequately prolonged without 
using both active drugs.
Better PFS were observed in the GS group for both 
patients with metastases and locally advanced disease; the 
PFS in patients with metastases was 3.0 and 5.4 months 
in the gemcitabine and GS groups, respectively, and PFS 
in patients with locally advanced cancer was 6.2 and 10.7 
months in the gemcitabine and GS groups, respectively. 
On the other hand, the OS was almost the same for the 
gemcitabine and GS groups in patients with metastases 
(HR 0.96), although a longer OS was observed in the GS 
group compared with the gemcitabine group in patients 
with locally advanced disease (HR 0.73). The reason 
for the differences in trends in OS observed between 
patients with locally advanced cancer and metastases was 
unclear. However, tumor shrinkage was greater in the 
GS group (29.3%) than the gemcitabine group (13.3%), 
which might have contributed to the prolonged survival 
in patients with locally advanced disease (HR = 0.73) by 
the mechanism of controlling micrometastasis. Tumor 
shrinkage was also slightly greater in S-1 alone group 
(21.0%) than gemcitabine alone group (13.3%), while OS 
in patients with locally advanced disease patients also 
showed a preferable trend in the S-1 group (HR = 0.81, 
Fig. 2). On the other hand, since tumor burden at meta-
static focuses had increased in patients with metastatic 
disease, the effect of reduced micrometastasis may not 
have given as much impact as OS prolongation in the GS 
group.
Although our results were obtained from a single clinical 
trial, the median follow-up of the survivors (29.8 months) 
and the number of events related to OS (795 events; 95.6%) 
were properly mature. Therefore, our results for survival 
are considered to be robust. We believe that the survival 
rates obtained in our study can serve as reference for future 
studies evaluating the outcomes of patients with pancreatic 
cancer who receive chemotherapy in East Asia (Supple-
mental Table 1).
In recent clinical studies of pancreatic cancer, patients 
with locally advanced disease have been evaluated sepa-
rately from those with metastatic disease. In our study, 
patients with both metastatic and locally advanced disease 
were enrolled. Our subgroup analyses revealed a trend 
toward better outcomes in patients with locally advanced 
disease than in those with metastatic disease, in all treat-
ment groups (Supplemental Table 1). Because the present 
study evaluated the same treatment regimens in patients 
with locally advanced disease and those with metastatic 
disease, our results might be useful as reference data for the 
future development of treatments for pancreatic cancer.
Our follow-up survey reconfirmed the non-inferiority 
of S-1 to gemcitabine and showed that S-1 can be used as 
a first-line treatment for both locally advanced and meta-
static pancreatic cancer. The detailed analysis of data for 
long-term survival in our study might contribute toward the 
development of new treatments for pancreatic cancer.
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